Pegylated Interferon Alfa-2a Maintenance Therapy and Liver Disease Progression in People Infected With Both HIV and Hepatitis C Virus (HCV)

Completed · Phase 2

Conditions studied: HIV Infections, Hepatitis C, Liver Disease

In brief

Infection with both HIV and hepatitis C virus (HCV) may result in serious and sometimes fatal liver disease. The purpose of this study was to test the effectiveness of long-term pegylated interferon alfa-2a (PEG-IFN) and ribavirin treatment in slowing liver disease progression in people infected with both HIV and HCV.

Key facts

Study ID
NCT00078403
Run by
National Institute of Allergy and Infectious Diseases (NIAID)
People needed
333
Starts
2004-07-01
Expected to finish
2009-02-01
Last updated by the study team
2021-11-08

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.